Tofacitinib Suppresses Several JAK-STAT Pathways in Rheumatoid Arthritis In Vivo and Baseline Signaling Profile Associates With Treatment Response

Tofacitinib Suppresses Several JAK-STAT Pathways in Rheumatoid Arthritis In Vivo and Baseline Signaling Profile Associates With Treatment Response

ObjectiveCurrent knowledge on the actions of tofacitinib on cytokine signaling pathways in rheumatoid arthritis (RA) is based on in vitro studies. Our study is the first to examine the effects of tofacitinib treatment on Janus kinase (JAK) - signal transducer and activator of transcription (STAT) pa...

Full description

Bibliographic Details
Main Authors: Maaria Palmroth, Krista Kuuliala, Ritva Peltomaa, Anniina Virtanen, Antti Kuuliala, Antti Kurttila, Anna Kinnunen, Marjatta Leirisalo-Repo, Olli Silvennoinen, Pia Isomäki
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-09-01
Series:Frontiers in Immunology
Subjects:
rheumatoid arthritis
cytokines
JAK inhibitor
monocytes
T cells
B cells
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2021.738481/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2021.738481/full

Similar Items